Sie suchten nach: niemann (Englisch - Slowenisch)

niemann-pick type c disease
niemann-pickova bolezen tipa c

• for niemann-pick type c disease:
21 • za niemann- pickovo bolezen tipa c:

dosage in niemann-pick type c disease
odmerjanje pri niemann-pickovi bolezni tipa c

zavesca is also used to treat progressive neurological symptoms in niemann-pick type c disease.
zdravilo zavesca se uporablja tudi za zdravljenje progresivnih nevroloških simptomov pri niemann- pickovi bolezni tipa c.

- monitoring growth if you are a child or adolescent with niemann-pick type c disease
- nadziranje rasti, če ste otrok ali mladostnik z niemann- pickovo boleznijo tipa c

- monitoring of blood platelet counts if you are a patient with niemann-pick type c disease
- nadziranje števila trombocitov v krvi, če ste bolnik z niemann- pickovo boleznijo tipa c

of these patients, 90 had type 1 gaucher disease, and 40 had niemann-pick type c disease.
med temi bolniki jih je imelo 90 gaucherjevo bolezen tipa 1 in 40 niemann- pickovo bolezen tipa c.

if you have niemann-pick type c disease, fats such as glycosphingolipids build up in the cells of your brain.
Če imate niemann-pickovo bolezen tipa c, se v celicah vaših možganov kopičijo maščobe kot so glikosfingolipidi.

there is limited experience with the use of zavesca in niemann-pick type c disease patients under the age of 4 years.
izkušenj z zdravljenjem z zdravilom zavesca pri bolnikih z niemann-pickovo boleznijo tipa c, starih pod 4 leta, je malo.

mild reductions in platelet counts without association to bleeding were observed in some patients with niemann-pick type c disease treated with zavesca.
pri nekaterih bolnikih z niemann-pickovo boleznijo tipa c, zdravljenih z zdravilom zavesca, so opazili blago zmanjšanje števila trombocitov, ki ni bilo povezano s krvavitvami.

in the study of niemann-pick type c disease, the improvement in eye movements was similar in patients treated with and without zavesca.
v študiji niemann-pickove bolezni tipa c je bilo izboljšanje sunkovitosti gibov z očmi podobno pri bolnikih, ki so jemali zdravilo zavesca in tistih, ki ga niso.

for niemann-pick type c disease, zavesca was studied in one main study involving 31 patients, 12 of whom were less than 12 years old.
zdravilo zavesca so za zdravljenje niemann-pickove bolezni tipa c proučevali v eni glavni študiji, v katero je bilo vključenih 31 bolnikov, od katerih jih je 12 bilo mlajših od 12 let.

data to support safety and efficacy of zavesca in niemann-pick type c disease come from a prospective open-label clinical trial and a retrospective survey.
podatki, ki podpirajo varnost in učinkovitost zdravila zavesca pri niemann-pickovi bolezni tipa c so bili zbrani v prospektivnem odprtem kliničnem preskušanju in v retrospektivni analizi.

reduced growth has been reported in some paediatric patients with niemann-pick type c disease in the early phase of treatment with miglustat where the initial reduced weight gain may be accompanied or followed by reduced height gain.
pri nekaterih pediatričnih bolnikih z niemann-pickovo boleznijo tipa c so poročali o zmanjšani rasti v zgodnji fazi zdravljenja z miglustatom, kjer lahko manjša rast spremlja začetno zmanjšano pridobitev teže ali ji sledi.

the recommended dose for the treatment of adolescent patients (12 years of age and above) with niemann-pick type c disease is 200 mg three times a day.
priporočeni odmerek za zdravljenje mladostnikov (starih 12 let in več) z niemann-pickovo boleznijo tipa c je 200 mg trikrat dnevno.

for niemann-pick type c disease, it is two capsules three times a day for patients aged 12 years and over; in younger patients, the dose depends on their weight and height.
pri niemann- pickovi bolezni tipa c je priporočeni odmerek za bolnike, starejše od 12 let, dve kapsuli trikrat na dan, pri mlajših bolnikih pa je odmerek odvisen od njihove telesne mase in višine.

approximately 37% of patients in clinical trials in type 1 gaucher disease, and 58% of patients in a clinical trial in niemann-pick type c disease reported tremor on treatment.
približno 37 % bolnikov v kliničnih preskušanjih z gaucherjevo boleznijo tipa 1 in 58 % bolnikov v kliničnih preskušanjih z niemann-pickovo boleznijo tipa c je poročalo o tremorju med zdravljenjem.

zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease (see sections 4.4, and 5.1).
zdravilo zavesca je indicirano za zdravljenje progresivne nevrološke manifestacije pri odraslih bolnikih in pediatričnih bolnikih z niemann-pickovo boleznijo vrste c (glejte poglavji 4.4, in 5.1).